[Clinical Research of EGFR and KRAS Mutation in Fine Needle Aspiration Cytology Specimens of Non-small Cell Lung Carcinoma].
BACKGROUND
Epidermal growth factor receptor (EGFR) and KRAS must be detected mutation status before patients of lung cancer use targeted drugs. The aim of this study is to elucidate the significance of EGFR and KRAS mutation in fine needle aspiration (FNA) cytology suspension specimens of non-small cell lung carcinoma.


METHODS
EGFR gene exons 18-21 and KRAS codons 12, 13 of exons 2 were performed by Real-time PCR methods in fine needle aspiration cytology suspension specimens of lymph nodes.


RESULTS
85 metastasis lymph nodes were detected in fine needle aspiration cytology samples of lung cancer. EGFR mutation rate was 37.3%. KRAS mutation rate was 7.2%. 19 formalin fixed paraffin-embedded tissue specimens were available and match cytology specimens. Analysis of EGFR mutation status in those samples revealed agreement with the results obtained in cytological samples (kappa=1.0). Clinical follow-up was available for 13 who presented with stage IV disease. Based on the identification of such mutations, these patients received subsequent therapy with a TKI in clinic. We observed two cases complete remission (16.7%) and 8 cases partial remission (66.7%) and three had ongoing stable disease.


CONCLUSIONS
Fine-needle aspiration cytology samples were detected EGFR and KRAS mutation. The method which collects samples was easier, simple and convenient. This method has higher application value in clinical treatment. .
Department of Pathology, Tumor hospital Chinese Academy of Medical Sciences, Beijing 100021, China.
Zhihui
Z
Zhang
Department of Pathology of Medicine University of Kunming, Kunming 650031, China.
Xilan
X
Wu
Department of Pathology, Tumor hospital Chinese Academy of Medical Sciences, Beijing 100021, China.
Jianming
J
Ying
Department of Pathology, Tumor hospital Chinese Academy of Medical Sciences, Beijing 100021, China.
Junling
J
Li
Department of Pathology, Tumor hospital Chinese Academy of Medical Sciences, Beijing 100021, China.
Tian
T
Qiu
Department of Pathology, Tumor hospital Chinese Academy of Medical Sciences, Beijing 100021, China.
Huiqin
H
Guo
Department of Pathology, Tumor hospital Chinese Academy of Medical Sciences, Beijing 100021, China.
Huan
H
Zhao
Department of Pathology, Tumor hospital Chinese Academy of Medical Sciences, Beijing 100021, China.
Ling
L
Shan
Department of Pathology, Tumor hospital Chinese Academy of Medical Sciences, Beijing 100021, China.
Yun
Y
Ling
D000328:Adult; D000368:Aged; D044963:Biopsy, Fine-Needle; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D066246:ErbB Receptors / Q000235:genetics* / Q000378:metabolism; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009154:Mutation; D059645:Mutation Rate; D011518:Proto-Oncogene Proteins / Q000235:genetics* / Q000378:metabolism; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins / Q000235:genetics* / Q000378:metabolism
C117307:KRAS protein, human; D011518:Proto-Oncogene Proteins; C512478:EGFR protein, human; D066246:ErbB Receptors; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins